# FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms

> **NCT06858618** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.** · enrollment: 47 (actual)

## Conditions studied

- Safety
- Antitumor Activity
- PK Profile

## Interventions

- **COMBINATION_PRODUCT:** FCN-338 + Azacitidine
- **COMBINATION_PRODUCT:** FCN-338 + erythromycin+ Ara-C

## Key facts

- **NCT ID:** NCT06858618
- **Lead sponsor:** Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-16
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06858618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06858618, "FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06858618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*